Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2003-08-18

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0960-894X(03)00561-4PMID 12873480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Potent and Selective Nonpeptide Antagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit1

  2002cited by this paper
• Chemokines, chemokine receptors and small-molecule antagonists: recent developments.

  2002cited by this paper
• The biology of chemokines and their receptors.

  2000cited by this paper
• Chemokine Receptor Antagonists

  2000cited by this paper
• Chapter 17. Chemokines: Targets for novel therapeutics

  2000cited by this paper
• Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration*

  1998cited by this paper
• Darstellung von Diaryl(3‐phenyl‐1,2,4‐triazol‐5‐yl)methanolen

  1975cited by this paper
• Studies of thiobenzoyl isocyanate—I

  1968cited by this paper
• The reaction of benzoyl isothiocyanate with hydrazine derivatives. Part I. Reaction with some alkyl hydrazines

  1967cited by this paper

• Targeting chemokine receptors from the inside-out: discovery and development of small-molecule intracellular antagonists.

  2022cites this paper
• Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead.

  2019cites this paper
• Lead Optimization in the Drug Discovery Process

  2019cites this paper
• Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

  2017cites this paper
• Thiocyanation of N,N-Dialkylhydrazonoyl Bromides: An Entry to Sulfur-Containing 1,2,4-Triazole Derivatives

  2017cites this paper
• Thiosemicarbazide Derivatives as Building Block in Synthesis of Target Heterocyclic Compounds with Their Antimicrobial Assessment

  2017cites this paper
• Role of the CXCL 8-CXCR 1 / 2 Axis in Cancer and Inflammatory Diseases

  2017cites this paper
• Synthesis, interactions, molecular structure, biological properties and molecular docking studies on Mn, Co, Zn complexes containing acetylacetone and pyridine ligands with DNA duplex.

  2016cites this paper
• Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models

  2015cites this paper
• 6-Arylpyrazine-2-carboxamides: A New Core for Trypanosoma brucei Inhibitors.

  2015cites this paper
• CXCR2 receptor antagonists: a medicinal chemistry perspective.

  2014cites this paper
• The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists.

  2014cites this paper
• Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease.

  2013cites this paper
• Cytokines in terms of QSAR. Review, evaluation and comparative studies

  2013cites this paper
• Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1).

  2013cites this paper
• Regulation of cellar cytokine production and NF-κB pathway by ginseng and ginsenosides

  2012cites this paper
• Molecular structure and EPR spectra studies of saccharinate complexes with 4-acetylpyridine

  2012cites this paper
• Low Molecular Weight CXCR2 Antagonists as Promising Therapeutics

  2011cites this paper
• Emerging role of extracellular nucleotides and adenosine in multiple sclerosis

  2011cites this paper
• Lead Discovery: The Process

  2010cites this paper
• 1 Lead Discovery : The Process

  2010cites this paper
• High Throughput Screening Approach to Lead Discovery

  2010cites this paper
• Discovery of small molecule human FPR1 receptor antagonists.

  2009cites this paper
• Discovery of small molecule human C5a receptor antagonists.

  2009cites this paper
• Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.

  2009cites this paper
• Erratum to: Spectroscopic and Thermal Studies of Mn(II), Fe(III), Cr(III) and Zn(II) Complexes Derived from the Ligand Resulted by the Reaction Between 4-Acetyl Pyridine and Thiosemicarbazide

  2009cites this paper
• Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.

  2008cites this paper
• Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.

  2008cites this paper
• Application Strategies for the Primary Structure–Activity Relationship Exploration

  2008cites this paper
• Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs

  2007cites this paper
• C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.

  2007cites this paper
• Synthesis of 1,2,4-triazole derivatives: binding properties on endothelin receptors.

  2007cites this paper
• Convenient synthesis of 4H-1,2,4-triazole-3-thiols using di-2-pyridylthionocarbonate

  2007cites this paper
• IL-8 receptor antagonist: basic research and clinical utility

  2007cites this paper
• Fragment-based drug discovery: what has it achieved so far?

  2007cites this paper
• ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.

  2006cites this paper
• Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.

  2006cites this paper
• Hit discovery and hit-to-lead approaches.

  2006cites this paper
• Cytokines as targets in chronic obstructive pulmonary disease.

  2006cites this paper
• N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.

  2006cites this paper
• Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.

  2006cites this paper
• Inhibiteurs de la tyrosinase et leur utilisation pour traiter les desordres hyperpigmentaires

  2006cites this paper
• Perspectives for cytokine antagonist therapy in COPD.

  2005cites this paper
• Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.

  2005cites this paper
• Perspectives for cytokine antagonist therapy in COPD.

  2005cites this paper
• Components of successful lead generation.

  2005cites this paper
• Selective optimization of side activities: another way for drug discovery.

  2004cites this paper
• As chronic obstructive pulmonary disease cannot be treated effectively by corticosteroids , what are the perspectives of specific cytokine antagonists for therapy ? Perspectives for cytokine antagonist therapy in COPD

  2004cites this paper
• Novel pyrimidine-based CXCR2 chemokine receptor antagonists

  2004cites this paper
• The Hit-to-Lead Process in Drug Discovery

  2004cites this paper
• A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice.

  2004cites this paper
• Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists.

  2004cites this paper
• Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.

  2004cites this paper
• Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.

  2004cites this paper